NCT06915870 is a NA clinical trial of Dapagliflozin 10 mg daily in Diabetes Mellitus, sponsored by Fatima Maqsood.

Who is sponsoring NCT06915870?

NCT06915870 is sponsored by Fatima Maqsood.

What drugs are being tested in NCT06915870?

Interventions in NCT06915870: Dapagliflozin 10 mg daily, Empagliflozin 10 MG OD.

What condition does NCT06915870 study?

NCT06915870 studies Diabetes Mellitus, Heart Failure.

Is NCT06915870 still recruiting?

NCT06915870 is currently completed. Last updated 8 April 2025.

Last reviewed 2025-04-08 · How we verify

NCT06915870

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

Completed NA Last updated 8 April 2025

What this trial tests

NA trial testing Dapagliflozin 10 mg daily in Diabetes Mellitus in 108 participants. Completed in 13 January 2025.

Timeline

12 July 2024

Primary endpoint
13 January 2025

13 January 2025

Quick facts

Lead sponsor	Fatima Maqsood
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	108
Start date	12 July 2024
Primary completion	13 January 2025
Estimated completion	13 January 2025
Sites	1 location across Pakistan

Drugs / interventions tested

Dapagliflozin 10 mg daily — full drug profile →
Empagliflozin 10 MG OD — full drug profile →

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →
Heart Failure — all drugs for Heart Failure →

Sponsor

Fatima Maqsood — full company profile →

Who can join

Adults 40 to 60, any sex, with Diabetes Mellitus or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06915870 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fatima Maqsood
Last refreshed: 8 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06915870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing